3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium-Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome

Overview

Journal Front Pharmacol

Date 2022 Jul 5

PMID 35784693

Authors

Juanjuan Zheng

Zhongxin Jiang

Yue Song

Shu Huang

Yuzhang Du

Xiaobao Yang

Yan Xiao

Zhihui Ma

Dakang Xu

Jing Li

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) has been reported to be associated with NLRP3 inflammasome activation. Therefore inhibiting inflammasome activation could be a new approach to treat IBD. Inflammasome inhibitors NLRP3-IN-2, JC124, and 3,4-methylenedioxy-β-nitrostyrene (MNS) were previously reported to exert anti-inflammatory effects in various disease models but not in the dextran sulfate sodium (DSS)-induced colitis model. Here, we showed that MNS was more efficient in inhibiting the secretion of interleukin-1β (IL-1β) by blocking oligomerization of apoptosis-associated speck-like protein (ASC) than NLRP3-IN-2 and JC124. To investigate the protective effects of MNS on enteritis, we administered intragastric MNS to DSS-induced colitis mice. The results demonstrated that MNS attenuated DSS-induced body weight loss, colon length shortening, and pathological damage. In addition, MNS inhibited the infiltration of macrophages and inflammatory cells and reduced IL-1β and IL-12p40 pro-inflammatory cytokines but had no significant effect on tumor necrosis factor α (TNF-α) and IL-6. Furthermore, we also found that the differentiation of IL-17Ainterferon-γ (IFN-γ)CD4 T cell was decreased in the colon after MNS treatment, which might be mediated by IL-1β, etc. cytokine release. Taken together, MNS alleviated DSS-induced intestinal inflammation by inhibiting NLRP3 inflammasome activation, which may function as an effective therapeutic for IBD.

Citing Articles

Fosfenopril Attenuates Inflammatory Response in Diabetic Dry Eye Models by Inhibiting the TLR4/NF-κB/NLRP3 Signaling Pathway.

Jiang K, Zhang F, Chen Y, Li X, Zhao X, Jiang P Invest Ophthalmol Vis Sci. 2024; 65(6):2.

PMID: 38829670 PMC: 11156208. DOI: 10.1167/iovs.65.6.2.

NLRP inflammasomes in health and disease.

Xu Z, Kombe Kombe A, Deng S, Zhang H, Wu S, Ruan J Mol Biomed. 2024; 5(1):14.

PMID: 38644450 PMC: 11033252. DOI: 10.1186/s43556-024-00179-x.

Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons.

Yu J, Zhao Z, Li Y, Chen J, Huang N, Luo Y Heliyon. 2024; 10(7):e28838.

PMID: 38596076 PMC: 11002585. DOI: 10.1016/j.heliyon.2024.e28838.

New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.

Kodi T, Sankhe R, Gopinathan A, Nandakumar K, Kishore A J Neuroimmune Pharmacol. 2024; 19(1):7.

PMID: 38421496 PMC: 10904444. DOI: 10.1007/s11481-024-10101-5.

IL-1β-mediated inflammatory responses in intervertebral disc degeneration: Mechanisms, signaling pathways, and therapeutic potential.

Li H, Pan H, Xiao C, Li H, Long L, Wang X Heliyon. 2023; 9(9):e19951.

PMID: 37809657 PMC: 10559578. DOI: 10.1016/j.heliyon.2023.e19951.

References

Saadane A, Masters S, DiDonato J, Li J, Berger M . Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol. 2007; 36(6):728-36. PMC: 1899341. DOI: 10.1165/rcmb.2006-0323OC. View

Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello C . Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol. 2004; 138(2):323-9. PMC: 1809217. DOI: 10.1111/j.1365-2249.2004.02599.x. View

Bauer C, Duewell P, Mayer C, Lehr H, Fitzgerald K, Dauer M . Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010; 59(9):1192-9. DOI: 10.1136/gut.2009.197822. View

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

Ambort D, Johansson M, Gustafsson J, Nilsson H, Ermund A, Johansson B . Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin. Proc Natl Acad Sci U S A. 2012; 109(15):5645-50. PMC: 3326483. DOI: 10.1073/pnas.1120269109. View

Patel D, Gaikwad S, Challagundla N, Nivsarkar M, Agrawal-Rajput R . Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis. Int Immunopharmacol. 2017; 54:375-384. DOI: 10.1016/j.intimp.2017.11.026. View

He Y, Varadarajan S, Munoz-Planillo R, Burberry A, Nakamura Y, Nunez G . 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2013; 289(2):1142-50. PMC: 3887181. DOI: 10.1074/jbc.M113.515080. View

McAlindon M, Hawkey C, Mahida Y . Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut. 1998; 42(2):214-9. PMC: 1726995. DOI: 10.1136/gut.42.2.214. View

Hayden M, Ghosh S . Shared principles in NF-kappaB signaling. Cell. 2008; 132(3):344-62. DOI: 10.1016/j.cell.2008.01.020. View

10.

Zhen Y, Zhang H . NLRP3 Inflammasome and Inflammatory Bowel Disease. Front Immunol. 2019; 10:276. PMC: 6403142. DOI: 10.3389/fimmu.2019.00276. View

11.

Place D, Kanneganti T . Cell death-mediated cytokine release and its therapeutic implications. J Exp Med. 2019; 216(7):1474-1486. PMC: 6605758. DOI: 10.1084/jem.20181892. View

12.

Mahida Y . The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000; 6(1):21-33. DOI: 10.1097/00054725-200002000-00004. View

13.

Fulp J, He L, Toldo S, Jiang Y, Boice A, Guo C . Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization. J Med Chem. 2018; 61(12):5412-5423. PMC: 6225534. DOI: 10.1021/acs.jmedchem.8b00733. View

14.

Conforti-Andreoni C, Spreafico R, Liang Qian H, Riteau N, Ryffel B, Ricciardi-Castagnoli P . Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18. J Immunol. 2011; 187(11):5842-50. DOI: 10.4049/jimmunol.1101408. View

15.

Zhivaki D, Kagan J . NLRP3 inflammasomes that induce antitumor immunity. Trends Immunol. 2021; 42(7):575-589. DOI: 10.1016/j.it.2021.05.001. View

16.

Kanneganti T, Lamkanfi M, Nunez G . Intracellular NOD-like receptors in host defense and disease. Immunity. 2007; 27(4):549-59. DOI: 10.1016/j.immuni.2007.10.002. View

17.

Famularo G, Trinchieri V, De Simone C . Inflammatory bowel disease. N Engl J Med. 2002; 347(24):1982-4; author reply 1982-4. View

18.

Petrovic S, Vasiljevska M, Obradovic S, Tarabar D, Doder R, Majstorovic I . Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice. Turk J Gastroenterol. 2020; 31(6):451-458. PMC: 7433996. DOI: 10.5152/tjg.2020.19454. View

19.

Mariathasan S, Weiss D, Newton K, McBride J, ORourke K, Roose-Girma M . Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006; 440(7081):228-32. DOI: 10.1038/nature04515. View

20.

Rock K, Latz E, Ontiveros F, Kono H . The sterile inflammatory response. Annu Rev Immunol. 2010; 28:321-42. PMC: 4315152. DOI: 10.1146/annurev-immunol-030409-101311. View